Stock listing
Frankfurt:BIX0 BioInvent International AB Aktie
German listing (Frankfurt) of BioInvent International AB · home listing Stockholm:BINV
Follow BioInvent International AB into a list and get an email when it puts out news.
Share price · FWB:BIX0
€0.269 EUR +0.003 (+1.1%)
Close on Nov 13, 2026
- Day range
- €0.257 – €0.269 EURNov 13, 2026
- Market cap
- €17.70M EURAt the close on Nov 13, 2026 · price × 65.80M shares outstanding
- 52-week range
- €0.215 – €3.233 EURLowest and highest trades, Nov 14, 2025 – Nov 13, 2026
- Traded on an average day
- €63 EURMedian day 0 shares · 56 days with no trades · last 3 months, Aug 13, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:BINV · Home | 2.75 SEK | -0.165 (-5.7%) | 215,209 | 2.91 | 2.945 | 2.66 | 2.915 | Close on Nov 16, 2026 |
| Frankfurt:BIX0 | €0.269 EUR | +0.003 (+1.1%) | — | €0.257 | €0.269 | €0.257 | €0.266 | Close on Nov 13, 2026 |
| OTC:BOVNF | $0.28 USD | 0.00 (0.0%) | — | $0.28 | $0.28 | $0.28 | $0.28 | Close on Nov 11, 2026 |
Daily closes
Last 3 months, Aug 13, 2026 – Nov 6, 2026 · FWB:BIX0 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.229 | -0.091 | -28.4% | €0.215 | €0.232 | €0.215 | 0 | |
| €0.320 | -0.031 | -8.8% | €0.320 | €0.320 | €0.320 | 0 | |
| €0.351 | +0.006 | +1.7% | €0.351 | €0.351 | €0.351 | 0 | |
| €0.345 | -0.071 | -17.1% | €0.345 | €0.345 | €0.345 | 0 | |
| €0.416 | -0.077 | -15.6% | €0.416 | €0.416 | €0.416 | 0 | |
| €0.493 | -0.333 | -40.3% | €0.493 | €0.493 | €0.493 | 907 | |
| €0.826 | -1.002 | -54.8% | €1.836 | €1.841 | €0.826 | 907 | |
| €1.828 | +0.033 | +1.8% | €1.828 | €1.828 | €1.823 | 582 | |
| €1.795 | +0.028 | +1.6% | €1.795 | €1.795 | €1.795 | 0 | |
| €1.767 | -0.024 | -1.3% | €1.767 | €1.767 | €1.767 | 0 | |
| €1.791 | -0.015 | -0.8% | €1.791 | €1.791 | €1.791 | 0 | |
| €1.806 | -0.098 | -5.1% | €1.806 | €1.806 | €1.806 | 0 | |
| €1.904 | +0.012 | +0.6% | €1.904 | €1.904 | €1.904 | 0 | |
| €1.892 | -0.174 | -8.4% | €1.892 | €1.892 | €1.892 | 0 | |
| €2.066 | +0.007 | +0.3% | €2.066 | €2.066 | €2.066 | 783 | |
| €2.059 | +0.015 | +0.7% | €2.059 | €2.059 | €2.059 | 0 | |
| €2.044 | +0.011 | +0.5% | €2.044 | €2.044 | €2.044 | 0 | |
| €2.033 | +0.040 | +2.0% | €2.033 | €2.033 | €2.033 | 0 | |
| €1.993 | -0.012 | -0.6% | €1.993 | €1.993 | €1.993 | 0 | |
| €2.005 | -0.009 | -0.4% | €2.005 | €2.005 | €2.005 | 0 | |
| €2.014 | +0.001 | 0.0% | €2.014 | €2.014 | €2.014 | 0 | |
| €2.013 | +0.015 | +0.8% | €2.013 | €2.013 | €2.013 | 0 | |
| €1.998 | +0.017 | +0.9% | €1.998 | €1.998 | €1.998 | 0 | |
| €1.981 | 0.000 | 0.0% | €1.981 | €1.981 | €1.981 | 0 | |
| €1.981 | +0.053 | +2.7% | €1.981 | €1.981 | €1.981 | 0 | |
| €1.928 | -0.051 | -2.6% | €1.928 | €1.928 | €1.928 | 0 | |
| €1.979 | +0.043 | +2.2% | €1.979 | €1.979 | €1.979 | 0 | |
| €1.936 | -0.014 | -0.7% | €1.936 | €1.936 | €1.936 | 0 | |
| €1.950 | +0.037 | +1.9% | €1.950 | €1.950 | €1.950 | 0 | |
| €1.913 | +0.106 | +5.9% | €1.913 | €1.913 | €1.913 | 0 | |
| €1.807 | -0.099 | -5.2% | €1.807 | €1.807 | €1.807 | 0 | |
| €1.906 | -0.012 | -0.6% | €1.906 | €1.906 | €1.906 | 0 | |
| €1.918 | +0.017 | +0.9% | €1.918 | €1.918 | €1.918 | 0 | |
| €1.901 | -0.045 | -2.3% | €1.901 | €1.901 | €1.901 | 0 | |
| €1.946 | +0.019 | +1.0% | €1.946 | €1.946 | €1.946 | 0 | |
| €1.927 | -0.025 | -1.3% | €1.927 | €1.927 | €1.927 | 0 | |
| €1.952 | +0.001 | +0.1% | €1.952 | €1.952 | €1.952 | 0 | |
| €1.951 | +0.025 | +1.3% | €1.951 | €1.951 | €1.951 | 0 | |
| €1.926 | -0.044 | -2.2% | €1.926 | €1.926 | €1.926 | 0 | |
| €1.970 | -0.028 | -1.4% | €1.970 | €1.970 | €1.970 | 0 | |
| €1.998 | -0.072 | -3.5% | €1.998 | €1.998 | €1.998 | 0 | |
| €2.070 | -0.010 | -0.5% | €1.999 | €2.072 | €1.994 | 2 | |
| €2.080 | -0.006 | -0.3% | €2.080 | €2.080 | €2.080 | 0 | |
| €2.086 | -0.044 | -2.1% | €2.086 | €2.086 | €2.086 | 0 | |
| €2.130 | +0.060 | +2.9% | €2.130 | €2.130 | €2.130 | 0 | |
| €2.070 | -0.068 | -3.2% | €2.070 | €2.070 | €2.070 | 0 | |
| €2.138 | +0.116 | +5.7% | €2.138 | €2.138 | €2.138 | 0 | |
| €2.022 | +0.023 | +1.2% | €2.022 | €2.022 | €2.022 | 0 | |
| €1.999 | -0.064 | -3.1% | €1.999 | €1.999 | €1.999 | 0 | |
| €2.063 | +0.086 | +4.4% | €2.063 | €2.063 | €2.063 | 0 | |
| €1.977 | -0.005 | -0.3% | €1.977 | €1.977 | €1.977 | 0 | |
| €1.982 | -0.145 | -6.8% | €2.039 | €2.060 | €1.980 | 1 | |
| €2.127 | -0.008 | -0.4% | €2.127 | €2.127 | €2.127 | 0 | |
| €2.135 | +0.016 | +0.8% | €2.135 | €2.135 | €2.135 | 0 | |
| €2.119 | +0.080 | +3.9% | €2.119 | €2.119 | €2.119 | 0 | |
| €2.039 | -0.077 | -3.6% | €2.039 | €2.039 | €2.039 | 0 | |
| €2.116 | +0.047 | +2.3% | €2.116 | €2.116 | €2.116 | 0 | |
| €2.069 | -0.096 | -4.4% | €2.069 | €2.069 | €2.069 | 0 | |
| €2.165 | -0.014 | -0.6% | €2.165 | €2.165 | €2.165 | 0 | |
| €2.179 | -0.039 | -1.8% | €2.179 | €2.179 | €2.179 | 0 | |
| €2.218 | +0.112 | +5.3% | €2.218 | €2.218 | €2.218 | 0 | |
| €2.106 | +0.071 | +3.5% | €2.106 | €2.106 | €2.106 | 0 |
Splits
1 split · FWB:BIX0 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation |
- Ticker
- Frankfurt:BIX0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Oct 28, 2026
BioInvent International resolves on a rights issue of approximately SEK 430 million subject to approval by an extraordinary general meeting and earlier publication of interim report January - September 2026
Latest earnings call · Feb 26, 2026
BioInvent International (Stockholm:BINV) Q4 2025 Earnings Call
Replay and transcript
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 49 slides
Calls
Replays
BioInvent International (Stockholm:BINV) Q4 2025 Earnings Call
Thu, Feb 26, 2026 · 8:00 AM ET
Watch TranscriptBioInvent International (Stockholm:BINV) Q3 2025 Earnings Call
Wed, Oct 29, 2025 · 9:00 AM ET
Watch Transcript
Latest news
BioInvent International resolves on a rights issue of approximately SEK 430 million subject to approval by an extraordinary general meeting and earlier publication of interim report January - September 2026
Oct 28, 2026
Closed €0.826 (-54.8%) on Oct 29, 2026
BioInvent International to present BI-1808 data in platinum-resistant recurrent ovarian cancer at ESMO 2026
Oct 18, 2026
Closed €2.07 (+0.3%) on Oct 19, 2026
BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology
Jun 1, 2026
Closed €2.99 (-6.0%) on Jun 1, 2026
BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026
May 12, 2026
Closed €2.12 (-1.7%) on May 12, 2026
BioInvent International AB: Interim Report January - March 2026
Apr 29, 2026
Closed €2.01 (+0.7%) on Apr 29, 2026
BioInvent International AB Publishes Annual Report 2025
Mar 31, 2026
Closed €1.93 (-1.9%) on Mar 31, 2026
BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis
Mar 26, 2026
Closed €2.12 (+1.2%) on Mar 26, 2026
Notice to Annual General Meeting in BioInvent International AB
Mar 24, 2026
Closed €1.99 (+2.9%) on Mar 24, 2026
BioInvent International AB: Year-End Report January 1 - December 31, 2025
Feb 26, 2026
Closed €2.41 (-0.2%) on Feb 26, 2026
Invitation to Presentation of BioInvent's Year-End Report 2025
Feb 26, 2026
Closed €2.41 (-0.2%) on Feb 26, 2026
Financings
Rights offering of new shares with preferential rights
Oct 28, 2026 · US$43.28M
Announced: about SEK 430M · DNB Carnegie Investment Bank AB (publ)
Dealers: DNB Carnegie Investment Bank AB (publ) (lead)
Buyers: Redmile (Subscription commitment; together with other existing shareholders approximately SEK 80 million); Van Herk (Subscription commitment; together with other existing shareholders approximately SEK 80 million); Forbion (Subscription commitment; together with other existing shareholders approximately SEK 80 million); HealthInvest (Subscription commitment; together with other existing shareholders approximately SEK 80 million); DNB Bank ASA (Guarantee undertakings, with others, up to approximately SEK 270 million); Schonfeld Global Master Fund L.P. (Guarantee undertakings, with others, up to approximately SEK 270 million); Anavio Capital Partners LLP (Guarantee undertakings, with others, up to approximately SEK 270 million)
Insiders: Shareholding board members and management intend to subscribe approximately SEK 0.6 million in total, including pro rata from CEO Martin Welschof and Chairman Leonard Kruimer
Use of proceeds: Strengthen financial position and fund clinical development of priority programs, principally BI-1808 and BI-1206 in solid tumors
Decks
Investor Presentation (October 2026)
Investor deck · 49 slides · October 2026
Investor Presentation (October 2026)
Investor deck · 46 slides · October 2026
Investor Presentation (September 2026)
Investor deck · 47 slides · September 2026
Investor Presentation (May 2026)
Investor deck · 43 slides · May 27, 2026
BioInvent International AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 14 in the last 12 months · 30 in all · newest Oct 28, 2026 · oldest 2025
- Calls
- 2 calls with a replay · 2 with a transcript · latest Feb 26, 2026
- Decks
- 23 decks · latest October 2026
Where BioInvent International AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:BINV · Home listing | Stockholm | Sweden | SEK |
| Aquis:BINVS | Aquis | United Kingdom | SEK |
| Stuttgart:BIX0 | Stuttgart | Germany | EUR |
| LS Exchange:A2QJRW | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2QJRW | Lang & Schwarz | Germany | EUR |
| gettex:BIX0 | gettex | Germany | EUR |
| Frankfurt:BIX0 · This page | Frankfurt | Germany | EUR |
| Dusseldorf:BIX0 | Dusseldorf | Germany | EUR |
| LSIN:0H22 | LSIN | United Kingdom | SEK |
| Munich:BIX0 | Munich | Germany | EUR |
| OTC:BOVNF | OTC | United States | USD |
| Aquis:BINVS | Aquis | United Kingdom | SEK |
| Turquoise:BINVS | Turquoise | United Kingdom | SEK |
Log in to ask 6ix AI your own questions about BioInvent International AB.